Target intelligence / Profile preview

Staphylococcus

Molecular classification
Bacterium, Pathogen
01

Overview

Staphylococcus is a genus of Gram-positive, non-motile bacteria that appear as spherical cocci in grape-like clusters under microscopic examination (StatPearls, 2023). While these organisms are frequently found as commensals on human skin and mucous membranes, they are also formidable opportunistic pathogens capable of causing a wide range of diseases from superficial abscesses to life-threatening systemic infections like sepsis and endocarditis (NIH, 2022). From a pharmacological perspective, 'Staphylococcal bacteria' refers to a whole pathogen genus rather than a specific molecular target like a receptor or enzyme; drugs instead target essential bacterial components such as Penicillin-Binding Proteins or the bacterial ribosome (PubMed, 2021). The clinical management of these infections is severely challenged by the prevalence of antibiotic resistance, particularly in strains like Methicillin-resistant Staphylococcus aureus (MRSA), which necessitates the use of specialized, often more toxic, antibiotic therapies (CDC, 2019). Ongoing research focuses on identifying novel targets within the bacterial cell to circumvent existing resistance mechanisms and biofilm-related survival strategies (Nature Reviews Microbiology, 2018).

Other names
StaphStaphylococciStaphylococcaceaeStaphylococcal bacteria
02

Mechanism of action

Antibacterial agents targeting Staphylococcus species function through various mechanisms, including the inhibition of cell wall peptidoglycan synthesis (e.g., beta-lactams and glycopeptides), inhibition of protein synthesis by binding to the 50S or 30S ribosomal subunits (e.g., linezolid, clindamycin), or disruption of the bacterial cell membrane (e.g., daptomycin) (StatPearls, 2023; NIH, 2022).

03

Biological functions

Bacterial colonizationInfection pathogenesisToxin productionBiofilm formation
04

Disease associations

InfectionBacteremiaPneumoniaInfective endocarditisSkin and soft tissue infectionOsteomyelitisToxic shock syndrome
05

Safety considerations

Rapid emergence of multi-drug resistance (e.g., MRSA, VRSA)Biofilm-mediated persistence and chronic infectionRisk of toxin-mediated diseases such as Toxic Shock Syndrome (TSS)Antibiotic-induced dysbiosis of the host microbiome
06

Interacting drugs

Vancomycin

7 more in the full profile.

07

Biomarkers

Coagulase productionCatalase productionmecA gene (methicillin resistance marker)nuc gene (Staphylococcus aureus-specific marker)Protein A (Spa)

Beyond the preview

Go deeper on Staphylococcus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Staphylococcus.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call